A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer

Prostate Cancer Clinical Trial

— CAPTAIN  

Official title:

Customized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05027477
• Other study ID #: GCP-10296
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2021
• Est. completion date: December 9, 2034

Study information

• Verified date: April 2024
• Source: Profound Medical Inc.
• Contact: Gina Clarke
• Phone: 416-689-8156
• Email: gclarke[@]profoundmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy.

Description:

The typical standard of care for patients with localized, intermediate risk prostate cancer is radical prostatectomy, which involves the surgical removal of the prostate. Although radical prostatectomy is effective in terms of controlling the cancer, it may leave men with significant long-term effects in urinary, sexual function like erectile dysfunction and/or incontinence (loss of bladder control), thus reducing quality of life. Preservation of continence (ability to control your bladder) and potency (ability to achieve erection and/or ejaculation) may be significant concerns for men. Targeted ablation of localized prostate cancer using MRI-guided technology is becoming a favorable option for many men who wish to have their cancer treated but do not wish to compromise their urinary and sexual functions. The TULSA Procedure is a new, minimally-invasive technique that uses real-time MRI-guided technology to guide the delivery of high-energy ultrasound to precisely, and in a customized fashion specific to you, heat and kill the prostate cancer tissue while protecting important surrounding body parts that are important for preserving urinary and sexual function. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like traditional surgery or minimally invasive surgery. The purpose of this research study is to: - Test whether the TULSA Study Procedure preserves or improves your quality of life (urinary, bowel and sexual functions) at 12 months post-study treatment compared to standard of care (radical prostatectomy). - Test how many subjects who undergo the TULSA Study Procedure are free from treatment failure by 3 years post-study treatment compared to subjects who undergo the standard of care (radical prostatectomy). Treatment failure is defined as undergoing other additional prostate cancer treatments, spreading of cancer or death caused by cancer. About 201 subjects will participate in this study with 67 randomly assigned to the radical prostatectomy group and 134 randomly assigned to the TULSA procedure group. Patients will have a 1 in 3 chance of being assigned to the radical prostatectomy group and a 2 in 3 chance of being assigned to the TULSA group. Following treatment, patients will be followed up for 10 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 201
• Est. completion date: December 9, 2034
• Est. primary completion date: December 9, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male
• Age 40 to 80 years, with >10 years life expectancy
• NCCN (favorable and unfavourable) intermediate-risk prostate cancer on biopsy acquired within last 12 months
• Stage =cT2c, N0, M0
• ISUP Grade Group 2 or 3 disease on TRUS-guided biopsy or in-bore biopsy
• PSA =20ng/mL within last 3 months
• Treatment-naïve
• Planned ablation volume is < 3 cm axial radius from urethra on mpMRI acquired within last 6 months

Exclusion Criteria:

• Inability to undergo MRI or general anesthesia
• Suspected tumor is > 30 mm from the prostatic urethra
• Prostate calcifications > 3 mm in maximum extent obstructing ablation of tumor
• Unresolved urinary tract infection or prostatitis
• History of proctitis, bladder stones, hematuria, history of acute urinary retention, severe neurogenic bladder
• Artificial urinary sphincter, penile implant, or intraprostatic implant
• Patients who are otherwise not deemed candidates for radical prostatectomy
• Inability or unwillingness to provide informed consent
• History of anal or rectal fibrosis or stenosis, or urethral stenosis, or other abnormality challenging insertion of devices

Related Conditions & MeSH terms

• Prostate Adenocarcinoma
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• Radical Prostatectomy
If you are in this group, you will get the standard of care treatment used to treat this type of cancer: radical prostatectomy. You will undergo this procedure as per standard clinical practice. A radical prostatectomy is a surgical procedure that removes the prostate gland. This is done by making a surgical incision and removing the prostate gland.
• TULSA Procedure
If you are in this group, you will get the TULSA Procedure. The TULSA Procedure is a minimally invasive procedure that uses directional ultrasound to produce very high temperature to ablate (destroy) targeted prostate tissue. The procedure is performed in a MRI suite (the physician can see the prostate at all times throughout the procedure) and uses the TULSA-PRO system to ablate prostate tissue. The procedure combines real-time MRI with robotically-driven directional thermal ultrasound to deliver predictable, physician-prescribed ablation of the prostate. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like in traditional surgery.

Locations

Country	Name	City	State
Canada	Lawson Health Research Institute, London Health Sciences Centre	London	Ontario
Canada	Sunnybrook Research Institute	Toronto	Ontario
Finland	Turku University Hospital/TYKS	Turku	Varsinais-Suomi
United States	Johns Hopkins School of Medicine	Baltimore	Maryland
United States	The University of Texas Southwestern Medical Center	Dallas	Texas
United States	Genesis Healthcare	Downey	California
United States	Indiana University	Indianapolis	Indiana
United States	Atlantic Urology Medical Group	Long Beach	California
United States	Comprehensive Urology Medical Group	Los Angeles	California
United States	Urology Group of Southern California	Los Angeles	California
United States	East Valley Urological Center	Mesa	Arizona
United States	Alarcon Urology Center	Montebello	California
United States	Yale Cancer Center	New Haven	Connecticut
United States	Pasadena Urological Medical Group	Pasadena	California
United States	The Urology Place	San Antonio	Texas
United States	Stanford Cancer Center	Stanford	California
United States	San Fernando Valley Urological Associates Medical Group, Inc.	West Hills	California

Sponsors (1)

Lead Sponsor	Collaborator
Profound Medical Inc.

Countries where clinical trial is conducted

United States,  Canada,  Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety endpoint - proportion of patients who maintain both urinary continence and erectile potency	Compare preservation of urinary continence and erectile potency, between the 2 arms. Urinary continence is defined as 'pad-free' (0 pads/day) (per EPIC question 5) and erectile potency is defined as erection firmness sufficient for penetration (per IIEF question 2).	12 months post-treatment
Primary	Efficacy endpoint - proportion of patients free from treatment failure	Compare the proportion of patients experiencing treatment failure, between the 2 arms. Treatment failure is defined as delivery of any additional intervention for prostate cancer (local or systemic, including adjuvant therapy), or metastatic disease, or prostate cancer-specific death.	36 months post-treatment
Secondary	Biochemical failure endpoint	Compare the proportion of patients with biochemical failure between the two arms. Biochemical failure is defined as PSA= 0.2 ng/mL for the RP arm or PSA nadir plus 2 ng/mL for the TULSA arm (adapted from Phoenix criteria).	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	Histological failure endpoint	Compare the proportion of patients who have clinically significant disease (defined as ISUP Grade Group 2 or higher) between the two arms.	At 12 month post treatment, and also at 24 months post treatment for patients who undergo a repeat TULSA
Secondary	mpMRI endpoint (for Tulsa arm only)	Characterize the effect of the TULSA Procedure ablation on diagnostic multi-parametric MRI, determined using PI-RADS V2 score, compared to baseline.	At 12 month post treatment, and also at 24 months post treatment for patients who undergo a repeat TULSA
Secondary	Salvage-free survival endpoint	Compare the proportion of patients who are salvage free, between the two arms. Salvage-free survival is defined as freedom from any salvage treatments after the assigned treatment, for both RP arm and TULSA arm. 1 repeat TULSA does not count as Salvage.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	Metastases-free survival endpoint	Compare the proportion of patients who are free from metastatic disease between the 2 arms, based on imaging.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	Prostate cancer-specific survival endpoint	Compare the proportion of patients who die of prostate cancer between the 2 arms.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	Overall survival endpoint	Compare the proportion of patients who die of any cause, between the 2 arms.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	Surgical complications endpoint	Compare the frequency and severity of all adverse events between the 2 arms, evaluated by attribution and reported in accordance with Clavien-Dindo classification.	At the following study visits post treatment: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5 years
Secondary	Penile rehabilitation endpoint	Compare the proportion of patients who undergo penile rehabilitation between the 2 arms (penile rehab includes implant insertion, medication/injection, traction or pump device).	At the following study visits post treatment: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5 years
Secondary	Penile length endpoint	Compare the change in penile length from baseline to after treatment, between the 2 arms, as measured by the study doctor.	At 1 month and 12 months post-treatment
Secondary	Blood loss endpoint	Compare the volume of blood lost between the two arms during treatment.	During the procedure and immediately after the procedure
Secondary	Transfusion volume endpoint	Compare the volume of transfused blood between the two arms during treatment.	During the procedure and immediately after the procedure
Secondary	Inpatient hospital stay endpoint	Compare the length of inpatient stay between the two arms.	Immediately after the procedure
Secondary	IIEF-15 Endpoint	Compare International Index of Erectile Function (IIEF-15) scores (for domains of sexual function) between the two arms at follow up, referenced to baseline. Low scores indicate a worse outcome.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	IPSS Endpoint	Compare International Prostate Symptom Score (IPSS) scores (for urinary function), between the two arms at follow up, referenced to baseline. Minimum score=0, Maximum score=35. Higher scores indicate a worse outcome.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	EPIC Endpoint	Compare (Expanded Prostate Cancer Index Composite) EPIC scores (for domains of urinary, sexual, bowel, and hormonal function), scored from 0 (worst) to 100 (best) between the two arms at follow up, referenced to baseline.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24 month, and 3, 4, 5, 6, 7, 8, 9, 10 years
Secondary	NRS Endpoint	Compare Numerical Rating Scale (NRS) ratings (which measures pain intensity), between the two arms at follow up, referenced to baseline. 0 indicates no pain and 10 indicates worst possible pain.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24, and 36 months.
Secondary	EQ-5D-5L Endpoint	Compare the EQ-5D-5L scores (which measures quality of life), between the two arms at follow up, referenced to baseline. Responses are coded as single-digit numbers expressing the severity level selected in each dimension (Mobility, self-care, usual activities, pain/discomfort and anxiety expression), where level 1 indicates no problem and level 5 indicates extreme problem.	At each visit post treatment throughout the total study follow up: 1, 3, 6, 9, 12, 18, 24, and 36 months.